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Introduction
Tinnitus is a frequent symptom in audiological
clinical practice, it happens alone, or in combina-
tion with other systemic or otologic diseases(1-3). It is
defined as an abnormal noise perceived in one or
both ears or in the head in which a patient has a
conscious hearing percept in absence of external
sound. The causes of the onset of disease can arise
from damage to the inner ear as a results of physi-
cal trauma, excessive noise, vascular insufficiency,
viral or bacterial infection and exposure to some
toxic drugs, such as aspirin and chemotherapeutics,
or as a result of aging(4-6).
The mechanisms underlying the development
of tinnitus are still not fully understood, the most
likely cause of tinnitus is changes in neural activity
in the brain, which is supported by both animal and
human studies. It has been reported that exposure to
intense sound, a manipulation able to modify the
functional status of the ear, can induce plastic phys-
iological changes which are more complex from
those occurring peripherally(4,7-10). Sound induced
injury have been correlated with an increase in
hyperactivity in the dorsal cochlear nucleus
(DCN)(11,12) the inferior colliculus and the primary
auditory cortex(13-15). Many researchers focused out
the attention on the modifications that occur in
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ABSTRACT
Tinnitus is a frequent symptom in audiological clinical practice characterized by an abnormal noise perceived in one or both
ears or in the head, in which a patient has a conscious hearing percept in absence of external sound. Tinnitus might be caused by a
homeostatic response of central dorsal cochlear nucleus auditory neurons that makes them hyperactive in compensation to auditory
input loss. One hypothesis suggests that tinnitus is a sensory form of epilepsy that involves the cochlear nucleus and the inferior col-
liculus, which display impairment in the electrical activity in the auditory system. This alteration determines a synaptic plasticity in
the dorsal cochlear nucleus that becomes a target for pharmacological compounds able to treat tinnitus. There is no effective drug
treatment for tinnitus, but different studies propose the use of cannabinoid receptors agonist for their anti-epileptic activity, although
their practical effects are still unclear. In this review, we want to analyze the emerging pharmacological approaches of cannabinoid
receptor agonists to the therapy of tinnitus.
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DCN following intense sound exposure inasmuch,
this area, is prominent as primary auditory center
that projects its output to the contralateral inferior
colliculus(16-20). Fusiform cells of the DCN are
responsible of tinnitus-related hyperactivity in the
cochlear nucleus. Moreover, recent studies show
that stimulation of the trigeminal nerve or ganglion
can modulate spontaneous activity fusiform cells in
DCN(21). These cells have higher levels of sponta-
neous activity in sound exposed animals than in the
unexposed controls(22, 23). In particular exposure to
salicylate as well as quinine cause increases in
spontaneous activity at several levels of the audito-
ry system and induced transient tinnitus(24-31).
Evidence that hyperactivity in the DCN represents a
source of tinnitus-generating signals comes from
studies in which electrophysiological recordings
from the DCN were complemented by behavioral
tests for tinnitus, suggesting that noise-exposure
conditions can also cause the development of tinni-
tus-like percepts(31-33). Moreover, when behavioral
and electrophysiological tests were conducted in
the same animals, a significant correlation was
found between the level of activity in the DCN and
the behavioral evidence for tinnitus(34).
Many pharmacological treatments are targeted
to control the activity of neurotransmitters, neuro-
modulators and voltage-gated channels that play a
pivotal role in the modulation of neuronal excitabil-
ity. Furthermore, because of several co-morbidities
of tinnitus, including anxiety, depression, dysfunc-
tion of the temporomandibular joint and modifica-
tion of neuronal excitability, other drugs have been
employed including antidepressants, benzodi-
azepines, antispasmodic drugs, drugs for neuropath-
ic pain, local anesthetics, voltage-gated sodium
channel blockers, antiepileptics(35-37).
Currently, no drugs exists with an indication
for tinnitus treatment, although many researches
pointed out the attention on the antiepileptic effects
played by the endocannabinoidergic system in some
parts of the CNS that might be useful in the treat-
ment of auditory injury.  
Materials and methods
The author’s search targeted evidence-based
guidelines, evidence-based summaries, systematic
reviews and recent experimental research on the
hyperactivity of tinnitus-generating signals and
endocannabinoidergic system. The keywords used
were “Tinnitus’’ or ‘‘Tinnitus in the cochlear nucle-
us” or “Pharmacological treatment of tinnitus” or
‘‘Endocannabinoidergic system” or ‘‘Cannabinoid
receptors’’. Through this simple strategy we identi-
fied more than 300 using two primary sources for
identify relevant information: PubMed and SCO-
PUS (last accessed via  PubMed and  SCOPUS on
December 2015)
Cannabinoid receptors distribution
Two types of cannabinoid receptors have been
identified, distributed in different tissues. CB1 and
CB2 receptors are distributed in many different
cells, with different mechanisms of signaling. It is
known that CB1 receptors are expressed mainly in
the central nervous system (CNS), while the CB2
receptors are localized primarily in cells to the
immune system(38), peripheral nervous system, testes
and retina, but recently their presence has been
detected in the brain, in particular microglial cells,
though at low concentrations(39). Both receptors are
coupled with Gi or Go protein, negatively to adeny-
lyl cyclase and positively to mitogen-activated pro-
tein (MAP) kinase. CB1 receptors, are represented
by two subtypes: CB1A and CB1B(40,41). CB1 recep-
tors are localized predominantly on pre-synaptic
terminals(42) and expressed in areas involved in
motor coordination and movement, such as cerebel-
lum, basal ganglia and substantia nigra; attention
and complex cognitive functions (cerebral cortex),
learning, memory and emotions (amygdala and hip-
pocampus)(43,44). This receptor is coupled to ion
channels through Gi/o proteins, positively to A-type
and inwardly rectifying potassium channels, and
negatively to N-type and P/Q-type calcium chan-
nels and to D-type potassium channels(45), in fact
CB1 activation inhibits cAMP-dependent protein
kinase (PKA), due to the decrease of cAMP.
Therefore, his mechanism causes inhibition of
calcium influx at presynaptic terminals, inhibiting
the release of classical neurotransmitters, such as
gamma-aminobutyric acid (GABA), acetylcholine,
noradrenaline and glutamate. It suggests how this
mechanism preserves the CNS from over-stimula-
tion or over-inhibition that may be caused by other
neurotransmitters. Upon which, the presynaptic
inhibition of neurotransmitter release by cannabi-
noids may turn out to be a key neuronal effect of
cannabinoids. Based on the distribution of cannabi-
noids receptors, different studies focused the atten-
tion on the spatial distribution of CB1 receptors in
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the auditory brain regions, in particular in the
CN(21). There is only a small literature on cannabi-
noid receptors in these regions and how they might
affect auditory function. Different studies have been
shown that CB1 receptor are expressed in both
Dorsal and Ventral Cochlear Nuclei (DCN and
VCN, respectively), modulating synaptic plasticity
in auditory nuclei(46-47) also reported the localization
of CB2 receptor CN, in spite of this second subtype
of cannabinoid receptor expression in the brain is
controversial(32,48). DCN fusiform cells are the prin-
cipal output neurons of the DCN, which project to
the contralateral inferior colliculus.
Therefore, hyperactivity of these neurons
could influence functional properties of inferior
colliculus neurons that could influence activity in
order structures such as the medial geniculate body
and auditory cortex(16-20). Fusiform cells receive
excitatory glutamatergic input via parallel fibers
from the granule cells of the DCN, as well as
inhibitory glycinergic input from cartwheel cells. In
this manner, fusiform cell hyperactivity associated
with tinnitus could result from an increase in gluta-
matergic excitation from the granule cells or a
reduction in glycinergic inhibition from the cart-
wheel cells, or some combination of both. Zhao et
al.(47) demonstrated that both fusiform and cartwheel
cells expressed diacylglycerol lipase (DAGL) a and
b, enzymes necessary for the production of the
endocannabinoid, 2- arachidonyl glycerol (2-AG).
The two forms of DAGL were found in the dendrit-
ic spines of cartwheel but not fusiform cells. It sug-
gests that the production of 2-AG is closer to paral-
lel fiber synapses in cartwheel cells compared to
fusiform cells. Tzounopoulos and colleagues(49)
demonstrated that CB1 receptors localized to paral-
lel fibers inhibited the release of glutamate onto
cartwheel and fusiform cells, but they also inhibit
the release of glycine on cartwheel cells (from other
cartwheel cells) and from cartwheel cells on
fusiform cells(23, 36) Zhao et al.(47) also showed that
glutamatergic terminals in the DCN expressed more
CB1 receptors on glutamatergic terminals than
glycinergic terminals, suggesting that the effects of
activation of CB1 receptors in the DCN would be
due to the increasing of excitation signals of
fusiform cells over their inhibition and that endo-
cannabinoid signaling might be a major factor
affecting the balance of excitation and inhibition in
this part of the central auditory system.
Moreover the increased activation of CB1
receptors in the DCN could lead to an increased
excitation of fusiform cells and to a possible hyper-
activity in the inferior colliculus (36). This increase
in multiunit spontaneous activity (hyperactivity) in
the DCN could be play a significant role in the
onset of tinnitus-generating signals.
Endocannabinoids and the neurotrasmission in
the Brain
Endocannabinoids (ECs), lipid-derived mole-
cules, produced on demand, activate CB receptors,
operating as retro negative feedback system(50,51) via
a Ca2+- dependent activation of endocannabinoid
synthesizing enzymes. These enzymes induce the
activation of pre-synaptic CB1(52-55), that, upon acti-
vation, attenuate Ca2+ influx into the pre-synaptic
terminal and thus transmitter release by blocking
vesicle fusion(56). This feedback mechanism is called
depolarization-induced suppression of inhibition(57-
58) (DSI) or depolarization-induced suppression of
excitation (DSE)(59), whether the released neuro-
transmitter exerts an inhibitory or an excitatory
action on the post-synaptic neurons(58). DSI and
DSE have been observed throughout the brain for
GABAergic and glutamatergic synapses to provide
a means for a cell to down-regulate its inputs in an
activity-dependent manner. In this way ECs modu-
late the neurotransmission in the brain, inducing
suppression of inhibitory and excitatory inputs(60, 61,
62-64). CB1 receptors in the DCN regulate the devel-
opment of DSI and DSE, as well as Long-Term
Depression (LTD), indicating that the endocannabi-
noid system is involved in the control of plasticity
in this part of the central auditory system(47, 65). Little
is known about the organization and function of
ECs signaling on auditory circuits(66, 67), despite the
knowledge of the effects of cannabinoids in the reg-
ulation of acoustic discrimination and auditory per-
ception. Some studies have been reported that CB1,
CB2 receptors, and the endogenous cannabinoid, 2-
arachidonylglycerol (2-AG), are expressed in the
cochlear nucleus and that they are involved in the
regulation of plasticity(68).
Cannabinoid drugs might be useful in the treat-
ment of tinnitus
Several studies showed that the DCN is
involved in the modulation of tinnitus in humans,
playing an important role in the etiology of this dis-
ease. Studies conducted in hamsters, displayed that
neurons become hyperactive in the DCN following
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exposure to intense sound(69). This hyperactivation
was originally observed as increase in spontaneous
activity at the multiunit level, although more recent
studies have demonstrated sound exposure, induced
hyperactivity in the DCN at the single unit level(33).
Respect to the evidence that the DCN is a possible
source of tinnitus-generating signals, as reported by
different studies(70); and consider the hyperactivation
of it, following exposure to intense noise, it is suit-
able investigate upon the role of cannabinoids in
the treatment of tinnitus. Based on theories that tin-
nitus is a form of sensory epilepsy that occurs as a
result of neuronal hyperactivity in certain parts of
the auditory CNS, particularly in CN and IC,
increasing evidences suggest the use of cannabinoid
drugs in the treatment of tinnitus. Lutz(71) reported
that cannabinoid drugs have antiepileptic effects in
some parts of the CNS and he has been demonstrat-
ed that in the hippocampus, CB1 receptor agonists
have anticonvulsant activity and exert antiepileptic
effects(36,72,73).
In this way, it is conceivable consider the use
of cannabinoids in the treatments of tinnitus,
because of their antiepileptic effects. Current stud-
ies confirm that many neurons in the DCN and
VCN have CB1 receptors and that therefore this
receptor type may be significant for auditory func-
tion. Subjective tinnitus and Cannabis have had a
long relationship and it has been suggested to cause
tinnitus, but anecdotal evidence suggests that tinni-
tus sufferers sometimes use it to relieve the condi-
tion. There are very few publications on this sub-
ject. Kempel et al.(66) reported that Cannabis reduced
the ability of humans to discriminate target tones of
specific frequency, location and duration. Hajos et
al.(67) reported that agonists at the cannabinoid CB1
receptor caused impairment in auditory sensory gat-
ing in rats. About the treatment of tinnitus in
human, it had been published only one case report,
in which tinnitus was treated and eliminated by the
administration of Dronabinol, a CB1 receptor ago-
nist, at a dose of 10 mg twice a day and then
reduced to 5 mg twice a day(74,75) investigate the rela-
tionship between CB1 receptor and tinnitus, using
an animal model of tinnitus, in which it had been
induced by salicylate injections. Rats displayed a
significant decrease in the number of neurons
expressing CB1 receptor and in one of the only two
studies, the authors investigated the effects of two
synthetic CB1 receptor agonist, WIN55,212-2 and
CP-55940.(76).
CB1 receptors appear to negatively regulate
the release of glutamate and it is possible that their
down-regulation during the development of tinnitus
is responsible for the neuronal hyperactivity associ-
ated with the condition. WIN55,212-2, and
CP55,940 could inhibit the behavioral manifesta-
tions of salicylate-induced tinnitus in rats in a con-
ditioned suppression task, but neither WIN55, 212-
2 (3.0 mg/kg s.c) nor CP55, 940 (0.1 or 0.3 mg/kg
s.c), significantly reduced conditioned behavior
associated with tinnitus. However, both 3 mg/kg
WIN55, 212-2 and 0.3 mg/kg CP55,940 did signifi-
cantly increase tinnitus-related behavior compared
to the vehicle control groups. To investigate tinni-
tus-related behavior, that realistically simulates the
common form of tinnitus in humans, it had been
caused by an acoustic injury. This study examined
the effect of 1:1 ratio of delta-9-THC (1.5mg/Kg,
s.c) and cannabidiol (1.5mg/kg, s.c),(77). All these
studies on experimental animal model displayed an
exacerbation of tinnitus and not a relieve. These
results suggest that CB receptors agonists may not
be useful in the treatment of tinnitus and that at cer-
tain doses; they could actually exacerbate the con-
dition(76).
Conclusion
The practical effects of cannabinoids for the
treatment of tinnitus, such a central injury, are still
unclear. Based on the hypothesis that tinnitus is a
form of sensory epilepsy that arise from neuronal
hyperactivation in auditory regions of the brain,
researchers focus their attention on the antiepileptic
mechanisms of cannabinoids on CB1 receptors, that
are very abundant in some areas of the brain.
Although cannabinoids exert anti-epileptic effects,
in the circuit of DCN, they facilitate an increase of
the excitation, rather than an inhibition, suggesting
that this hyperactivity is part of the cause of tinni-
tus, such as it is still not clear whether the down-
regulation of CB1 receptors, might be part of a
hyperactivity or compensatory response to it.
Nevertheless, study of model of partial epilepsy in
adult male rats, prompt the possibility to use antag-
onists/inverse agonist CB receptors in co-adminis-
tration with agonists to increase their antiepileptic
effects(78, 79). This prompt the possibility to use
antagonists or inverse agonists CB1 receptors might
relieve the hyperactivity in the DCN and then
relieve tinnitus.
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